Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Moberg Derma AB Signs Distribution Agreement with Ana Darou P.J.S. for Nalox/Emtrix
Moberg Derma AB announced that it has entered into a distribution agreement with Ana Darou P.J.S. (Ana Darou) for Nalox/Emtrix for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Ana Darou is granted exclusive rights to market and sell Nalox/Emtrix in Iran. Moberg Derma AB assumes production and supply responsibility.
Latest Developments for Moberg Derma AB
- Moberg Derma AB Issues Long Term Financial Guidance
- Moberg Derma AB Discontinues Clinical Development of Limtop Following Phase II Clinical Trial
- Moberg Derma AB Completes Acquisition of Alterna LLC and Executes Issue in Kind
- Moberg Derma AB Receives Final Results from Phase II Study of MOB-015 in Patients with Onychomycosis; Company Initiates New Study
Latest Key Developments in Pharmaceuticals
- H Lundbeck A/S Announces Positive Results from Pre-Clinical Studies with Vortioxetine
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Announces Changes of General Manager
- Merck & Co Inc Announces $5 Billion Accelerated Share Repurchase
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Share this
- Link this
- Digg this
Follow Reuters